# Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis

> **NCT06644638** · — · COMPLETED · sponsor: **Novartis** · enrollment: 3632 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06644638
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-15
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 3632 (ACTUAL)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06644638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06644638, "Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06644638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*